Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago

Medroxyprogesterone Acetate

Female Sex hormones Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Cancer

Provera is indicated for ovulation suppression and for the treatment of endometriosis. It is also used as adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma, and for the treatment of hormonally-dependent recurrent breast cancer in post-menopausal women.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Pharmacodynamics: When given by intramuscular injection, Medroxyprogesterone Acetate provides a progestational effect that lasts for an extended period. It works by suppressing the pituitary gland's secretion of gonadotropins, which in turn prevents follicular maturation, producing long-term anovulation in women of reproductive age. In men, Medroxyprogesterone Acetate injection suppresses Leydig cell function, meaning it suppresses the body's own production of testosterone.

Pharmacokinetics: Given by injection, Medroxyprogesterone Acetate is a long-acting progestational steroid. The 150 mg/ml formulation takes about 27 days to fall to half its initial concentration. Its long duration of action comes from how slowly it is absorbed from the injection site. The main metabolite that has been identified is 6-alpha-methyl-6 beta 17 alpha, 21 trihydroxy-4-pregnene-3, 20-dione-17 acetate, which is excreted in the urine.

Pregnancy & Breastfeeding

Not recommended during the first 4 months of pregnancy.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Ovulation suppression: Shake the Medroxyprogesterone Acetate injectable suspension gently just before use so that the dose given is a uniform suspension. The recommended dose is 150 mg/ml of this injectable suspension every three months, given by intramuscular injection into the gluteal or deltoid muscle. The first injection should be given during the first 5 days after the start of a menstrual period; within 5 days after delivery if not breastfeeding; or at or after six weeks after delivery if exclusively breastfeeding. Based on limited experience, some investigators prefer giving a second injection of Medroxyprogesterone Acetate before 90 days to control troublesome bleeding. The third and later injections should be given at separate 90-day intervals. If abnormal bleeding continues, appropriate investigations should be carried out to rule out the possibility of organic disease. Uterine curettage may be needed on rare occasions.